Wyzwania diagnostyczno-terapeutyczne w leczeniu grzybic układowych u dzieci z chorobami hematologicznymi i nowotworami

Diagnostic and therapeutic challenges in the treatment of systemic fungal infections in children with hematological disorders and hematological malignances

Michał Matysiak

Katedra i Klinika Pediatrii, Hematologii i Onkologii Warszawskiego Uniwersytetu Medycznego

Michał Matysiak
Katedra i Klinika Pediatrii, Hematologii i Onkologii WUM
ul. Żwirki i Wigury 63 A,02-091 Warszawa

Wpłynęło: 04.11.2019
Zaakceptowano: 05.12.2019
Opublikowano on-line: 10.01.2020

Cytowanie / Citation

Matysiak M. Wyzwania diagnostyczno-terapeutyczne w leczeniu grzybic układowych u dzieci z chorobami hematologicznymi i nowotworami
Zakażenia XXI wieku 2019;2(6):257–261.
doi: 10.31350/zakazenia/2019/6/Z2019042

Wersja elektroniczna / Article ePDF

Streszczenie:
Inwazyjne zakażenia grzybicze są istotnymi przyczynami zachorowalności i umieralności dzieci z chorobami hematologicznymi i nowotworami, a także po przeszczepie komórek macierzystych. Celem tej pracy jest przedstawienie aktualnie dostępnych leków oraz metod diagnostycznych i terapeutycznych stosowanych w inwazyjnych zakażeniach grzybiczych.

Słowa kluczowe: inwazyjne zakażenia grzybicze, diagnostyka, leczenie, terapia deeskalacyjna

Abstract:
Invasive fungal diseases remain important causes of morbidity and mortality in children with hematological disorders, haematological malignancies and in patients after stem cell transplantation. The objective of this review is the presentation of currently available drugs, and diagnostic and therapeutic recommendations including clinical examination, imaging methods and laboratory tests for invasive fungal infections.

Key words: invasive fungal infection diagnostics, therapy, de-escalation therapy

  1. Kontoyiannis DP. Invasive mycoses; strategies for effective management. Am J Med 2012;125(Suppl 1):S25–S38. doi: 1016/j.amjmed.2011.10.009
  2. Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Seminars in Haematology 2009;46(3):212–229. doi: 1053/j.seminhematol.2009.03.003
  3. Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Seminars in Haematology 2009;46(3):259–268. doi: 1053/j.seminhematol.2009.03.002
  4. Bailey LCh, Reilly AF, Rheingols SR. Infections in paediatric patients with hematologic malignancies. Semin Hematol. 2009;46(3):313–324. doi: 1053/j.seminhematol.2009.03.010
  5. Mellinghoff SC, Panse J, Alakel N i wsp.Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol 2018;97(2):197–207. doi: 1007/s00277-017-3196-2
  6. Phillips K, Cirrone F, Ahuja T i wsp. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome. J Oncol Pharm Pract 2019;25(2):398–403. doi: 1177/1078155218806975
  7. Rüping MJ, Vehreschild JJ, Cornely OA. Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome–still an open question? Leuk Lymphoma 2010;51(1):20–26. doi: 3109/10428190903242602.
  8. Sarina B, Mariotti J, Bramanti S i wsp. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling. Transpl Infect Dis 2018;20(4):e12906. doi: 1111/tid.12906
  9. Reinwald M, Bosch T, Hofmann WK i wsp. Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors. Biomark Insights 2015;10:5–68. doi: 4137/BMI.S22430
  10. Kyi C, Hellmann MD, Wolchok JD i wsp. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2014;2:19. doi: 1186/2051-1426-2-19
  11. Donnelly JP, Chen SC, Kauffman CA i wsp. Revision and update if the consesnsus definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium Clinical Infectious Diseases 2019:pii:ciz1008. doi: 1093/cid/ciz1008. [Epub ahead of print]
  12. Fisher BT, Ross RK, Localio AR, Prasad PA, Zaoutis TE. Decreasing rates of invasive candidiasis in pediatric hospitals across the United States. Clin Infect Dis 2014;58(1):74–77. doi: 1093/cid/cit679
  13. Steinbach WJ, Roilides E, Berman D i wsp. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J 2012;31:1252–1257. doi: 1097/INF.0b013e318273742
  14. Pana ZD, Roilides E, Warris A, Groll AH, Zaoutis T. Epidemiology of invasive fungal disease in children. J Pediatric Infect Dis Soc 2017;6(Suppl 1):S3–S11. doi: 1093/jpids/pix046
  15. Benjamin DK Jr, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003;112:634–640. doi: 1542/peds.112.3.634
  16. McCarthy MW, Kalasauskas D, Petraitis V, Petraitiene R, Walsh TJ. Fungal infections of the central nervous system in children. J Pediatric Infect Dis Soc 2017;6(3):123–133. doi: 1093/jpids/pix059
  17. van Asbeck EC, Clemons KV, Stevens DA. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol 2009;35(4):283–309. doi: 3109/10408410903213393
  18. Robinson JL, Davies HD, Barton M i wsp. Characteristics and outcome of infants with candiduria in neonatal intensive care—a Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. BMC Infect Dis 2009;9:183. doi: 1186/1471-2334-9-183
  19. Katragkou A, Fisher BT, Groll AH, Roilides E, Walsh TJ. Diagnostic imaging and invasive fungal diseases in children. J Pediatric Infect Dis Soc 2017;6(Suppl 1):S22–S31. doi: 1093/jpids/pix055
  20. Burgos A, Zaoutis TE, Dvorak CC i wsp. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008;121(5):1286–1294. doi: 1542/peds.2007-2117
  21. Thomas KE, Owens CM, Veys PA, Novelli V, Costoli V. The radiological spectrum of invasive aspergillosis in children: a 10-year review. Pediatr Radiol 2003;33(7):453–460. doi: 1007/s00247-003-0919-4
  22. Pasmans HL, Loosveld OJ, Schouten HC, Thunnissen F, van Engelshoven JM. Invasive aspergillosis in immunocompromised patients: findings on plain film and (HR)CT. Eur J Radiol 1992;14:37–40.
  23. Bal C, Kumar R. Potential role of 18FFDG PET/CT in patients with fungal infections. AJR Am J Roentgenol 2014;203(1):180–189. doi: 2214/AJR.13.11712
  24. Huppler AR, Fisher BT, Lehrnbecher T, Walsh TJ, Steinbach WJ. Role of molecular biomarkers in the diagnosis of invasive fungal diseases in children. J Pediatric Infect Dis Soc 2017;6(Suppl 1):S32–S44. doi: 1093/jpids/pix054
  25. Fisher BT, Zaoutis TE, Park JR i wsp. Galactomannan antigen testing for diagnosis of invasive aspergillosis in pediatric hematology patients. J Pediatric Infect Dis Soc 2012;1(2):103–111. doi: 1093/jpids/pis044
  26. Lehrnbecher T, Robinson PD, Fisher BT i wsp. Galactomannan, β-D-glucan, and polymerase chain reaction-based assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis. Clin Infect Dis 2016;63:1340–1348. doi: 1093/cid/ciw592
  27. Kowalczyk JR, Stefaniak MJ, Kałwak K, Matysiak M i wsp. Standardy postępowania diagnostyczno-terapeutycznego w inwazyjnej chorobie grzybiczej u dzieci: rekomendacje Polskiego Towarzystwa Onkologii i Hematologii Dziecięcej. Postępy Nauk Medycznych 2016;8:528–533.
  28. Mikulska M, Furfaro E, Del Bono V i wsp. Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012;67(7):1746–1748. doi: 1093/jac/dks111
  29. Mikulska M, Calandra T, Sanguinetti M i wsp. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: Recommendations from the third European Conference on Infections in Leukemia. Crit Care 2010;14:R222. doi: 1186/cc9365
  30. Salvatore CM, Chen TK, Toussi SS i wsp. (1→3)-β-d-Glucan in cerebrospinal fluid as a biomarker for Candida and Aspergillus infections of the central nervous system in pediatric patients. J Pediatric Infect Dis Soc 2016;5(3):277–286. doi: 1093/jpids/piv014
  31. Marchetti O, Lamoth F, Mikulska M i wsp. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012;47(6):846–854. doi: 1038/bmt.2011.178
  32. Lamoth F, Cruciani M, Mengoli C i wsp. Beta-glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: A systematic review and meta-analysis of cohort studies from the third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012;54(5):633–643. doi: 1093/cid/cir897
  33. White PL, Wingard JR, Bretagne S i wsp. Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing. Clin Infect Dis 2015;61(8):293–303. doi: 1093/cid/civ507
  34. Schauwvlieghe AFAD, Vonk AG, Buddingh EP i wsp. Detection of azolesusceptible and azole-resistant Aspergillus coinfection by cyp51A PCR amplicon melting curve analysis. J Antimicrob Chemother 2017;72(11):3047–3050. doi: 1093/jac/dkx262
  35. Chong GL, van de Sande WW, Dingemans GJ i wsp. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol 2015;53(3):868–874. doi: 1128/JCM.03216-14
  36. White PL, Posso RB, Barnes RA. Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs directly from plasma samples. J Clin Microbiol 2017;55(8):2356–2366. doi: 1128/JCM.00411-17
  37. Dzierżanowska-Fangrat K, Gil L, Jakubas B i wsp. Rekomendacje terapii inwazyjnej choroby grzybiczej u pacjentów z nowotworami hematologicznymi lub poddawanych przeszczepieniu komórek krwiotwórczych. Postępy Nauk Medycznych 2015;28(6):411–418.
  38. Sulik-Tyszka B, Bieńko D, Saran O i wsp. Terapia deeskalacyjna zakażeń grzybiczych. Zakażenia XXI wieku 2018;1(5):231–235. doi: 31350/zakazenia/2018/5/Z2018037
  39. Jaffal K, Poissy J, Rouze A i wsp. De-escalation of antifungal treatment In critically ill patients with suspected invasive Candida infection: incidence, associated factors and safety. Ann Intensive Care 2018;8(1):49. doi: 1186/s13613-018-0392-8
  40. van Engen Casamayor M, Kim S i wsp. De-escalation strategy using micafungin for the treatment of systemic Candida infections: budget impact in France and Germany Clinico-Economics and Outcomes Research 2017;9:763–774. doi: 2147/CEOR.S141548
  41. Masterton RG, Casamayor M, Musingarimi P i wsp. De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections. J Med Economics 2013;16(11):1344–1356. doi: 3111/13696998.2013.839948.
  42. Pappas PG, Kauffman CA, Andes DR i wsp. Clinical practice guideline
    for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;62(4):e1–e50. doi: 1093/cid/civ933.
  43. Cuenca-Estrella M, Verweij PE, Arendrup MC i wsp. ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012;18(7):9–18. doi: 1111/1469–0691.12038.
  44. Tissot F, Agrawal S, Pagano L i wsp. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017;102(3):433–444. doi: 3324/haematol.2016.152900.
  45. Dzierżanowska D, Dzierżanowska-Fangrat K. Przewodnik terapii inwazyjnych zakażeń grzybiczych. α-medica Press, Bielsko-Biała, 2012, pp. 22–63.
  46. Czuczwar M, Komarnicka J, Woroń J i wsp. Postępowanie w inwazyjnych zakażeniach grzybiczych na oddziałach intensywnej terapii u dorosłych pacjentów bez neutropenii w świetle obowiązujących rekomendacji. Forum Zakażeń 2016;7(2):77–84. doi: 15374/FZ2016011.

Konflikt interesów: Artykuł przygotowany we współpracy z Gilead Sciences Poland Sp. z o.o., jednakże prezentowana w nim treść ma charakter obiektywny.